Jane Street Group LLC Has $78,000 Stock Holdings in ProKidney Corp. (NASDAQ:PROK)

Jane Street Group LLC decreased its holdings in shares of ProKidney Corp. (NASDAQ:PROK) by 14.6% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 40,530 shares of the company’s stock after selling 6,945 shares during the quarter. Jane Street Group LLC’s holdings in ProKidney were worth $78,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also modified their holdings of PROK. Rhumbline Advisers boosted its position in ProKidney by 8.8% during the second quarter. Rhumbline Advisers now owns 76,190 shares of the company’s stock worth $187,000 after purchasing an additional 6,181 shares during the period. The Manufacturers Life Insurance Company boosted its holdings in ProKidney by 54.6% during the third quarter. The Manufacturers Life Insurance Company now owns 37,981 shares of the company’s stock valued at $73,000 after acquiring an additional 13,415 shares during the period. AQR Capital Management LLC bought a new position in shares of ProKidney in the second quarter worth about $50,000. Intech Investment Management LLC acquired a new position in shares of ProKidney during the 3rd quarter worth about $46,000. Finally, MetLife Investment Management LLC boosted its position in shares of ProKidney by 90.6% in the third quarter. MetLife Investment Management LLC now owns 62,660 shares of the company’s stock valued at $120,000 after acquiring an additional 29,789 shares during the period. Institutional investors own 51.59% of the company’s stock.

ProKidney Price Performance

Shares of NASDAQ:PROK opened at $1.58 on Thursday. The business’s fifty day moving average price is $1.82 and its two-hundred day moving average price is $2.01. ProKidney Corp. has a fifty-two week low of $1.18 and a fifty-two week high of $4.44. The stock has a market capitalization of $460.83 million, a price-to-earnings ratio of -2.87 and a beta of 1.32.

ProKidney (NASDAQ:PROK) last announced its earnings results on Tuesday, November 12th. The company reported ($0.14) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.14). Research analysts expect that ProKidney Corp. will post -0.57 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Separately, JPMorgan Chase & Co. initiated coverage on ProKidney in a research note on Monday, September 30th. They set a “neutral” rating on the stock. Three analysts have rated the stock with a hold rating and two have given a buy rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and an average target price of $4.50.

ProKidney Company Profile

ProKidney Corp., a clinical-stage biotechnology company, provides transformative proprietary cell therapy platform for treating various chronic kidney diseases in the United States. The company's lead product is Renal Autologous Cell Therapy (REACT), an autologous homologous cell admixture, which has completed Phase I clinical trial for REACT in patients with congenital anomalies of the Kidney and Urinary Tract (CAKUT), as well as in Phase III and Phase II clinical trials for the treatment of moderate to severe diabetic kidney disease.